Plural Separated Benzene Rings In Z Moiety Patents (Class 514/539)
-
Publication number: 20090163589Abstract: Novel calcilytic compounds and methods of using them are provided.Type: ApplicationFiled: February 26, 2009Publication date: June 25, 2009Inventors: Robert W. Marquis, Linda N. Casillas, Joshi M. Ramanjulu, James Francis Callahan
-
Patent number: 7538124Abstract: Biphenylcarboxamide compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes.Type: GrantFiled: June 24, 2008Date of Patent: May 26, 2009Assignee: Janssen Pharmaceutica N.V.Inventors: Lieven Meerpoel, Leo Jacobs Jozef Backx
-
Publication number: 20090120339Abstract: The present inventions generally relate to compositions and methods for providing agricultural chemicals comprising active ingredients (A.I.s) combined with a top dressing for application to cultivated areas of turfgrass. Specifically, the compositions are in the form of moist formulations for providing top dressings comprising active ingredients. Further, the inventions relate to compositions and methods for delivering active ingredients simultaneously with a top dressing composition to golf course turf.Type: ApplicationFiled: October 17, 2008Publication date: May 14, 2009Inventors: A. Ronald Detweiler, Nancy M. Dykema, Joseph M. Vargas, JR.
-
Publication number: 20090076113Abstract: Novel biphenylcarboxamides of the formula (I) There is further provided a plurality of processes for preparing these compounds and their use for controlling unwanted microorganisms, and also novel intermediates and their preparation.Type: ApplicationFiled: December 5, 2006Publication date: March 19, 2009Applicant: Bayer CropScience AGInventors: Ralf Dunkel, Hans-Ludwig Elbe, Jorg Nico Greul, Herbert Gayer, Arnd Voerste, Ulrike Wachendorff-Neumann, Peter Dahmen
-
Publication number: 20090069421Abstract: The present invention provides a novel crystal polymorph of ethyl (?)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride which can be determined by characteristic diffraction peaks of the powder X-ray diffraction or the like, and obtained from ethyl (?)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxyacetate by a specific method.Type: ApplicationFiled: April 24, 2006Publication date: March 12, 2009Applicant: Kissei Pharmaceutical Co., Ltd,Inventors: Kiyoshi Kasai, Michio Toda
-
Publication number: 20090062340Abstract: Novel biaromatic compounds having the structural formula (I) below: are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions.Type: ApplicationFiled: November 6, 2008Publication date: March 5, 2009Applicant: Galderma Research & DevelopmentInventors: LAURENCE CLARY, CLAIRE BOUIX-PETER, MICHEL RIVIER, PASCAL COLLETTE, ANDRE JOMARD
-
Patent number: 7491748Abstract: A carboxylic acid derivative of formula (I): wherein R1 is —COOH, —COOR6, etc.; A is a single bond, alkylene, etc.; R2 is alkyl, alkoxy, etc.; B is a carbocyclic ring or a heterocyclic ring; Q is alkylnene-Cyc2, etc.; D is a linking chain; and R3 is alkyl, a carbocyclic ring or a heterocyclic ring, or a non-toxic salt thereof. The compound of formula (I) binds to PGE2 receptor, especially subtypes EP3 and/or EP4 and show the antagonizing activity, are useful for the prevention and/or treatment of diseases induced pain, itch, urticaria, allergy, urinary frequency, urinary disturbance, Alzheimer's disease, cancer, dysmenorrhea, endometriosis, etc.Type: GrantFiled: August 8, 2002Date of Patent: February 17, 2009Assignee: Ono Pharmaceutical Co., Ltd.Inventors: Kousuke Tani, Masaki Asada, Kaoru Kobayashi, Masami Narita, Mikio Ogawa
-
Patent number: 7476650Abstract: Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like and PGPH activities of the 20S proteasome can be selectively inhibited with the inventive compounds. The peptide-based compounds include an electron withdrawing group adjacent to the ring functionality, and the peptide include at least three peptide units. Among other therapeutic utilities, the peptide-based compounds exhibit anti-inflammatory and inhibition of cell proliferation, involving therapeutic applications for these compounds.Type: GrantFiled: June 17, 2004Date of Patent: January 13, 2009Assignee: Yale UniversityInventors: Craig M. Crews, Mikael Elofsson, Ute Splittgerber, Kyung Bo Kim
-
Publication number: 20080318976Abstract: ?-Hydroxy amide derivatives of the general formula (I) are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. R2a is selected from (1) a group selected from Ra. (2)(CH2)nNRbC(O)Ra. (3)(CH2)nNRbSO2Rd. (4)(CH2)nNRbCO2Ra.(5)(CH2)k-heterocycle optionally substituted with 1 to 3 groups independently selected from halogen.nitro, cyano.ORa.SRa.C1-4 alkyl and C1-3 haloakyl wherein said heterocycle is (a) a 5-membered heteroaromatic ring having a ring heteroatom selected from N.O and S. and optionally having up to 3 additional ring nitrogen atoms wherein said ring is optionally benzo-fused; or (b) a 6-membered heteromatic ring containing from 1 to 3 ring nitrogen atoms and N-oxydes thereof. Wherein said ring is optionally benzo-fused. (6)(CH2)kCO2Ra. and (7)(CH2)C(O)NRbRc.Type: ApplicationFiled: December 17, 2004Publication date: December 25, 2008Inventors: Michael R. Wood, Neville J. Anthony, Mark G. Bock, Scott D. Kuduk
-
Publication number: 20080306150Abstract: Agents useful for the treatment of various metabolic disorders, such as insulin resistance syndrome, diabetes, polycystic ovary syndrome, hyperlipidemia, fatty liver disease, cachexia, obesity, atherosclerosis and arteriosclerosis are disclosed. Formula (I), wherein n is 1 or 2; m is 0, 1, 2, 3, or 4; q is 0 or 1; t is 0 or 1; R is hydrogen, halo, hydroxy, alkyl having 1 or 2 carbon atoms, perfluoromethyl, alkoxy having 1 or 2 carbon atoms, and perfluoromethoxy; R is alkyl having from 1 to 3 carbon atoms; R3 is hydrogen, halo, alkyl having from 1 to 3 carbon atoms, or alkoxy having from 1 to 3 carbon atoms; one of R4 and R5 is hydrogen or hydroxy and the other is hydrogen; or R4 and R5 together are ?O; R6 is hydrogen or alkyl having one, two, three, four or five carbon atoms; or a pharmaceutically acceptable salt of the compound. Alternatively, the agent can be a pharmaceutically acceptable salt of the compound of Formula (I).Type: ApplicationFiled: January 22, 2007Publication date: December 11, 2008Applicant: WELLSTAT THERAPEUTICS CORPORATIONInventors: Shalini Sharma, Reid W. von Borstel
-
Publication number: 20080300287Abstract: The present invention provides a compound of formula (I), (II), (III) and (IV) as defined herein and pharmaceutically acceptable derivatives thereof. The present invention further provides use of the compounds of the present invention in the treatment of bacterial infection and in the treatment of HIV infection. Also provided are pharmaceutical compositions comprising the compounds of the present invention.Type: ApplicationFiled: September 21, 2005Publication date: December 4, 2008Applicant: UNIVERSITY OF WOLLONGONGInventors: Timothy Patrick Boyle, John Barnard Bremner, Zinka Brkic, Jonathan Alan Victor Coates, Neal Kevin Dalton, John Deadman, Paul Anthony Keller, Jody Morgan, Stephen Geoffrey Pyne, David Ian Rhodes, Mark James Robertson
-
Publication number: 20080292688Abstract: The present invention relates to a composition and a method for preparing a liposome, the liposome including a lipid bilayer and an aqueous core contains a hydrophobic or a hydrophilic drug and a component—Vitamin E derivative (d-? tocopheryl polyethylene glycol 1000 succinate; TPGS). TPGS is able to increase the encapsulation efficiency of drug in liposome as well as to enhance the stability of drug in liposomes. Such liposome is capable to increase the skin permeation of drugs. The preparation method comprises the following steps: (1) adding the drug to a Vitamin E derivative solution to form a mixture; and (2) adding at least one phosphatidyl choline to the mixture, after hydration from either sonication or homogenization.Type: ApplicationFiled: March 17, 2008Publication date: November 27, 2008Applicant: Industrial Technology Research InstituteInventors: Ae-June Wang, Pei-Lin Wang, Wan-Ko Chen, Chi-Heng Jian
-
Patent number: 7456217Abstract: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 13, 2005Date of Patent: November 25, 2008Assignee: Mitsubishi Tanabe Pharma CorporationInventors: Takayuki Kawaguchi, Sumihiro Nomura, Mikiko Tsukimoto, Toshiyuki Kume, Ila Sircar
-
Publication number: 20080280901Abstract: The present invention relates to a use of a specific alpha-arylmethoxyacrylate derivative, or its pharmacologically acceptable salt or solvate for preventing and treating metabolic bone diseases.Type: ApplicationFiled: June 22, 2005Publication date: November 13, 2008Applicants: Korea Research Institute of Chemical Technology, Oscotec Inc.Inventors: Bum Tae Kim, Yong Ki Min, Yeon Soo Lee, Jung Nyoung Heo, Hyuk Lee, No Kyun Park, Jung-Keun Kim, Se-Won Kim, Seon-Yle Ko
-
Publication number: 20080275087Abstract: Biphenylcarboxamide compounds of formula (I) methods for preparing such compounds, pharmaceutical compositions comprising said compounds as well as the use of said compounds as a medicine for the treatment of hyperlipidemia, obesity and type II diabetes.Type: ApplicationFiled: June 24, 2008Publication date: November 6, 2008Inventors: Lieven Meerpoel, Leo Jacobus Jozef Backx
-
Publication number: 20080269220Abstract: A compound represented by the formula (1): wherein each symbol is as defined in the specification, and a salt thereof and a prodrug thereof unexpectedly have superior GPR40 receptor agonist activity, superior in the properties as a pharmaceutical product such as stability and the like, and can be a safe and useful pharmaceutical agent as a drug for the prophylaxis or treatment of GPR40 receptor related pathology or diseases such as diabetes and the like.Type: ApplicationFiled: March 14, 2005Publication date: October 30, 2008Inventors: Tsuneo Yasuma, Nobuyuki Negoro, Shinobu Sasaki
-
Publication number: 20080261816Abstract: An inventive flowable granular material for adhesion to foliage is provided, which material includes peanut hull fragments as a preferably majority lightweight component, a heavy weight component mixed therewith to improve the flowability of the resultant granular material, and a solvent to aid in the transfer of the foliar active agent to a leaf surface and foliar adhesion. Related particle size distributions and densities are described. Also provided is a process for promoting plant growth comprising: broadcast distributing the inventive flowable granular material to adhere to foliar surfaces; and releasing the foliar active agent onto the foliar surface.Type: ApplicationFiled: April 23, 2008Publication date: October 23, 2008Applicant: The Andersons, Inc.Inventor: Timothy D. Birthisel
-
Publication number: 20080255111Abstract: A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.Type: ApplicationFiled: July 1, 2005Publication date: October 16, 2008Applicant: SANKYO COMPANY LIMITEDInventors: Naoki Terasaka, Ayano Hiroshima
-
Publication number: 20080221210Abstract: The invention provides compounds of formula (I) or a pharmaceutically acceptable ester, amide, solvate or salt thereof, including a salt of such an ester or amide, and a solvate of such an ester, amide or salt. The invention also provides the use of such compounds in the treatment or prophylaxis of a condition mediated by a thyroid receptor. Formula (I), wherein R1, R2, n, Y, Y?, R3, R4, W and R5 are as defined in the specification.Type: ApplicationFiled: March 22, 2005Publication date: September 11, 2008Applicant: Karo Bio ABInventors: Ana Maria Garcia Collazo, Thomas Anders Wilson Norin, Neerai Garg, Anton Joakim Lofstedt, Tomas Fredrik Hansson, Lars Jesper Hallberg, Peter Brandt
-
Patent number: 7423028Abstract: Injectable pharmaceutical compositions are described comprising sodium diclofenac, a ?-cyclodextrin and a polysorbate, suitable for subcutaneous and intramuscular administration.Type: GrantFiled: June 21, 2005Date of Patent: September 9, 2008Assignee: Ibsa Institut Biochemique S.A.Inventors: Giorgio Zoppetti, Nadia Puppini, Marco Pizzutti
-
Publication number: 20080214393Abstract: Compounds of formula (I) wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.Type: ApplicationFiled: September 20, 2005Publication date: September 4, 2008Applicant: SYNGENTA CROP PROTECTION, INC.Inventors: Andre Jeanguenat, Anthony Cornelius O'Sullivan
-
Patent number: 7399789Abstract: The present invention relates to compounds of the formula or pharmaceutically acceptable salts thereof, useful for delivering agents having the capacity to diagnose, treat or prevent bone injury or disease to the bone for interaction therewith.Type: GrantFiled: February 14, 2007Date of Patent: July 15, 2008Assignee: University of Louisville Research FoundationInventors: William M. Pierce, Leonard C. Waite, K. Grant Taylor
-
Publication number: 20080139505Abstract: The present invention provides compounds of formula (I): pharmaceutical compositions thereof, and methods of using the same, processes or preparing the same, and intermediates thereof.Type: ApplicationFiled: November 15, 2005Publication date: June 12, 2008Inventors: Thomas Daniel Aicher, Guillermo S. Cortez, Todd Michael Groendyke, Albert Khilevich, James Allen Knobelsdorf, Fredrik Pehr Marmsater, Jeffrey Michael Schkeryantz, Tony Pisal Tang, Nicholas Andrew Magnus
-
Patent number: 7375120Abstract: Novel PDF inhibitors and novel methods for their use are provided.Type: GrantFiled: April 16, 2003Date of Patent: May 20, 2008Assignee: Smithkline Beecham CorporationInventors: Siegfried B. Christensen, IV, Maxwell D. Cummings, Jinhwa Lee, Jia-ning Xiang
-
Patent number: 7365085Abstract: Disclosed is a compound having the formula: pharmaceutically acceptable salts or solvates thereof and pharmaceutical compositions containing the same, wherein the structural variables are as defined herein. The compounds, salts and solvates of this invention are useful as LXR agonists.Type: GrantFiled: March 26, 2003Date of Patent: April 29, 2008Assignee: SmithKline Beecham CorporationInventors: Ajita Bhat, John Jeffrey McAtee, Scott K. Thompson, James S. Frazee, Lara S. Kallander, Chun Ma, Joseph Marino, Michael J. Neeb, Robert A. Stavenger
-
Patent number: 7351719Abstract: The present invention relates to amide compounds of general formula I wherein the groups and residues A, B, b, W, X, Y, Z, R1, R2 and R3 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one amide according to the invention. In view of the MCH receptor-antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia and diabetes.Type: GrantFiled: October 31, 2003Date of Patent: April 1, 2008Assignee: Boehringer Ingelheim Pharma GmbH & Co. KGInventors: Dirk Stenkamp, Stephan Georg Mueller, Gerald Juergen Roth, Philipp Lustenberger, Klaus Rudolf, Thorsten Lehmann-Lintz, Kirsten Arndt, Ralf Lotz, Martin Lenter, Heike-Andrea Wieland
-
Patent number: 7345095Abstract: The present invention relates to compounds of the Formula I wherein R1, R2, R3, m, and n are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods for treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.Type: GrantFiled: October 6, 2006Date of Patent: March 18, 2008Assignee: Pfizer IncInventors: Michael A. Brodney, Karen J. Coffman
-
Patent number: 7323188Abstract: A composition for controlling harmful bio-organisms comprising (a) at least one imidazole compound represented by formula (I): wherein R represents a lower alkyl group or a lower alkoxy group; and n represents an integer of 1 to 5, as an active ingredient, and (b) at least one inorganic phosphorus compound and/or at least one fungicide for Phycomycetes as an active ingredient or (c) a spreader as an activity-enhancing ingredient, and a method for controlling harmful bio-organisms comprising applying the composition for controlling harmful bio-organisms onto harmful bio-organisms.Type: GrantFiled: July 21, 2005Date of Patent: January 29, 2008Assignee: Ishihara Sangyo Kaisha, Ltd.Inventors: Norifusa Matsuo, Shigeru Mitani, Satoshi Araki, Yasuko Takii, Tomona Yamaguchi
-
Patent number: 7314888Abstract: A compound or a salt thereof having the atom corresponding to N3 and the two or more atoms selected from N1, N2, N4 and N5, said atoms constitute the pharmacophore represented by the following formula: and inhibits the activity of transcription factor AP-1 and is useful as an agent for preventing and treating the diseases into which over expression of AP-1 participates and as an AP-1 inhibitor.Type: GrantFiled: November 5, 1999Date of Patent: January 1, 2008Assignee: Toyama Chemical Co., Ltd.Inventors: Hisaaki Chaki, Tadakazu Takakura, Keiichi Tsuchida, Hironori Kotsubo, Yukihiko Aikawa, Shuichi Hirono, Shunichi Shiozawa
-
Patent number: 7304037Abstract: The present invention relates to cytostatics which have a tumor-specific action as a result of linkage to ?v?3 integrin antagonists via preferred linking units which can be selectively cleaved by elastase, i.e. by an enzyme which can especially be found in tumor tissue. The preferred linking units provide sufficient stability of the conjugate of cytostatic and ?v?3 integrin antagonist in biological fluids and, at the same time, the desired intracellular action within tumor cells as a result of its specific enzymatic or hydrolytic cleavability with release of the cytostatic.Type: GrantFiled: March 8, 2002Date of Patent: December 4, 2007Assignee: Bayer AkiengesellschaftInventors: Hans-Georg Lerchen, Jörg Baumgarten, Andreas Schoop, Markus Albers
-
Patent number: 7262223Abstract: The present invention relates to the use of amidine compounds in the treatment of amyloid-related diseases. In particular, the invention relates to a method of treating or preventing an amyloid-related disease in a subject comprising administering to the subject a therapeutic amount of an amidine compound.Type: GrantFiled: January 23, 2004Date of Patent: August 28, 2007Assignee: Neurochem (International) LimitedInventors: Xianqi Kong, Xinfu Wu, David Migneault
-
Patent number: 7247654Abstract: The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel 3,4-disubstituted benzamidines and benzylamines, or a stereoisomer or pharmaceutically acceptable salt form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor Xa, factor XIa, factor IXa, and/or factor VIIa. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.Type: GrantFiled: June 1, 2004Date of Patent: July 24, 2007Assignee: Bristol-Myers Squibb CompanyInventors: E. Scott Priestley, Xiaojun Zhang
-
Patent number: 7223793Abstract: The present invention relates to phenolic acid derivatives of the formula I and compositions for the preventing and the treating blood lipid level-related diseases comprising the phenolic acid derivatives. The compounds have excellent effects of reducing blood lipid level, inhibiting cholesterol metabolism-related enzymes and preventing and treating blood lipid level-related diseases.Type: GrantFiled: December 4, 2002Date of Patent: May 29, 2007Assignee: Bionutrigen Co., Ltd.Inventors: Songhae Bok, Sangku Lee, Taesook Jeong, Euneai Kim, Surksik Moon, Myungsook Choi, Byunghwa Hyun, Chulho Lee, Yangkyu Choi, Gootaeg Oh
-
Patent number: 7220749Abstract: The invention describes novel nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one nitrosated and/or nitrosylated cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or, optionally, at least one therapeutic agent. The invention also provides novel compositions comprising at least one COX-2 selective inhibitor, that is optionally sitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.Type: GrantFiled: June 10, 2003Date of Patent: May 22, 2007Assignee: NitroMed, Inc.Inventors: L. Gordon Letts, David S. Garvey
-
Patent number: 7217706Abstract: This invention relates to new propanolamine derivatives or salts thereof represented by the following formula [I]: Wherein each symbol is as defined in the specification or salts thereof which have gut selective sympathomimetic, anti-ulcerous, anti-pancreatitis, lipolytic, anti-urinary incontinence and anti-pollakiuria activities, to processes for the preparation thereof, to a pharmaceutical composition comprising the same and to a method for the prevention and/or treatment diseases indicated in the specification to a human being or an animal.Type: GrantFiled: February 14, 2002Date of Patent: May 15, 2007Assignee: Astellas Pharma Inc.Inventors: Kiyoshi Taniguchi, Minoru Sakurai, Naoaki Fujii, Kumi Hosoi, Yasuyo Tomishima, Hisashi Takasugi, Hajime Sogabe, Hirofumi Ishikawa, Naomi Hanioka
-
Patent number: 7208520Abstract: The present invention provides ethyl (?)-2-[4-[2-[[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethyl]amino]ethyl]-2,5-dimethylphenoxy]acetate hydrochloride, crystalline forms thereof and pharmaceutical compositions containing them, which have excellent ?3-adrenoceptor stimulating effects, therapeutic effects on pollakiuria or urinary incontinence and storage stabilities and are useful as a medicament.Type: GrantFiled: August 27, 2002Date of Patent: April 24, 2007Assignee: Kissei Pharmaceutical Co., Ltd.Inventors: Hidetoshi Isawa, Yukihiko Hotei, Kiyoshi Kasai, Junichi Sonehara, Satoshi Akahane, Hiromu Harada
-
Patent number: 7196220Abstract: The present invention relates to compounds of the formula or pharmaceutically acceptable salts thereof, useful for delivering agents having the capacity to diagnose, treat or prevent bone injury or disease to the bone for interaction therewith.Type: GrantFiled: December 22, 2004Date of Patent: March 27, 2007Assignee: University of Louisville Research Foundation, Inc.Inventors: William M. Pierce, Jr., Leonard C. Waite, K. Grant Taylor
-
Patent number: 7163942Abstract: The present invention relates to compounds of the Formula I wherein R1, R2, R3, m, and n are as defined. Compounds of the Formula I have activity inhibiting production of A?-peptide. The invention also relates to pharmaceutical compositions and methods for treating disorders and diseases, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.Type: GrantFiled: March 11, 2005Date of Patent: January 16, 2007Assignee: Pfizer Inc.Inventors: Michael A. Brodney, Karen J. Coffman
-
Patent number: 7153869Abstract: This invention relates to a series of substitituted amino acids of Formula I pharmaceutical compositions containing them and intermediates used in their manufacture. The compounds of the invention are small molecules which bind to the erythropoietin receptor and compete with the natural ligand for binding to this receptor.Type: GrantFiled: March 12, 2004Date of Patent: December 26, 2006Inventors: Peter J. Connolly, Victor T. Bandurco, Steven K. Wetter, Sigmond Johnson, Jacqueline Bussolari, William V. Murray
-
Patent number: 7105564Abstract: The present invention provides novel compounds having a dual antagonistic activity against thromboxane A2 receptor and prostaglandin D2 receptor and pharmaceutical compositions comprising them. A compound of the formula (I): wherein R1 is —CH2—CH?CH—CH2—CH2—CH2—COOR2 or —CH?CH—CH2—CH2—CH2—COOR2; R2 is hydrogen or alkyl; m is 0 or 1; p is 0 or 1; X1 and X3 each is independently optionally substituted aryl or optionally substituted heteroaryl; X2 is a bond, —CH2—, —S—, —SO2—, —CH2—O—, —O—CH2—, —CH2—S—, —S—CH2—, or the like; X4 is —CH2—, —CH2—CH2—, —C(?O)—, or the like, have a dual antagonistic activity against both a thromboxane A2 receptor and a prostaglandin D2 receptor.Type: GrantFiled: March 2, 2000Date of Patent: September 12, 2006Assignee: Shionogi & Co., Ltd.Inventors: Tsunetoshi Honma, Yoshiharu Hiramatsu, Akinori Arimura
-
Patent number: 7071188Abstract: The present invention relates to plant-protecting active ingredient mixtures having synergistically enhanced action and to a method of improving the growth of plants, comprising applying to the plants or the locus thereof at least three active ingredient components together. Specifically, a mixture of fludioxonil (I), metalaxyl (II) and a strobilurin fungicide (III) achieves markedly enhanced action against plant pathogens and is suitable for improving the growth of plants when applied to plants, parts of plants, seeds, or at their locus of growth.Type: GrantFiled: June 13, 2002Date of Patent: July 4, 2006Assignee: Syngenta Crop Protection, Inc.Inventor: Clifford Watrin
-
Patent number: 7071358Abstract: Arylsulfonamidobenzyl alcohols, amines and sulfonamides are provided which are useful in treating lipid disorders, metabolic diseases and cell-proliferative diseases.Type: GrantFiled: January 29, 2003Date of Patent: July 4, 2006Assignee: Amgen Inc.Inventors: Xian Yun Jiao, Frank Kayser, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
-
Patent number: 7049341Abstract: N-Benzoylureidocinnamic acid derivatives, processes for preparing them and their use The invention relates to N-benzoylureidocinnamic acid derivatives and to their physiologically tolerated salts and physiologically functional derivatives. The invention thus relates to compounds of formula I, in which the radicals have the given meanings, and to their physiologically tolerated salts and processes for preparing them. The compounds are, for example, suitable for use as antidiabetic agents.Type: GrantFiled: June 6, 2003Date of Patent: May 23, 2006Assignee: Aventis Pharma Deutschland GmbHInventors: Karl Schoenafinger, Elisabeth Defossa, Dieter Kadereit, Erich Von Roedern, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Karl-Ulrich Wendt
-
Patent number: 7034045Abstract: The present invention provides certain monofluoroalkyl derivatives useful for potentiating glutamate receptor function in a mammal and therefore, useful for treating a wide variety of conditions, such as psychiatric and neurological disorders.Type: GrantFiled: April 17, 2000Date of Patent: April 25, 2006Assignee: Eli Lilly and CompanyInventors: David Michael Bender, Buddy Eugene Cantrell, Andrew Hendley Fray, Winton Dennis Jones, William David Miller, David Mitchell, Richard Lee Simon, Hamideh Zarrinmayeh, Dennis Michael Zimmerman
-
Patent number: 7030160Abstract: The invention relates to phenoxypropanolamines, to pharmaceutical compositions containing them, to processes for preparing them, and to the method of use thereof in the treatment of diseases that are improved by beta-3 agonist action.Type: GrantFiled: May 29, 2001Date of Patent: April 18, 2006Assignee: Sanofi-AventisInventors: Laura Barzaghi, Philippe R. Bovy, Roberto Cecchi, Tiziano Croci, Stefano Romagnano
-
Patent number: 7026501Abstract: The present invention relates to a phenylalanine derivative of Formula (I) wherein X1 is a halogen atom, X2 is a halogen atom, Q is a CH2R— is a carboxyl group which may be esterified; or a pharmaceutically acceptable salt thereof.Type: GrantFiled: August 27, 2001Date of Patent: April 11, 2006Assignee: Tanabe Seiyaku Co., Ltd.Inventors: Takayuki Kawaguchi, Sumihiro Nomura, Mikiko Tsukimoto, Toshiyuki Kume
-
Patent number: 7022735Abstract: The present invention provides a microbicide composition for plants, containing at least two active ingredient components in an amount producing synergistic activity, together with an appropriate filler, wherein component I is the compound 2-[.alpha.-{[(.alpha.Type: GrantFiled: July 9, 2002Date of Patent: April 4, 2006Assignee: Bayer AktiengesellschaftInventors: Paul Margot, Gertrude Knauf-Beiter
-
Patent number: 6927224Abstract: The present invention provides, inter alia, triphenylethylene derivatives, such as, 3-{4-[6-(3-Methoxy-phenyl)-8,9-dihydro-7H-benzocyclohepten-5-yl]-phenyl}-acrylic acid, as selective estrogen receptor modulators. Also provided are methods for the treatment and/or prevention of estrogen stimulated diseases in mammals including breast, uterine, ovarian, prostrate and colon cancer, osteoporosis, cardiovascular disease, and benign proliferative disorders, as well as pharmaceutical compositions of the compounds of the present invention.Type: GrantFiled: August 9, 2002Date of Patent: August 9, 2005Assignee: Bristol Myers Squibb CompanyInventors: Robert F. Kaltenbach, Simon P. Robinson, George L. Trainor
-
Patent number: 6919369Abstract: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.Type: GrantFiled: August 19, 2002Date of Patent: July 19, 2005Assignee: Genentech, Inc.Inventors: Ignacio Aliagas-Martin, Dean R. Artis, Michael S. Dina, John A. Flygare, Richard A. Goldsmith, Regina A. Munroe, Alan G. Olivero, Richard Pastor, Thomas E. Rawson, Kirk D. Robarge, Daniel P. Sutherlin, Kenneth J. Weese, Aihe Zhou, Yan Zhu
-
Patent number: RE39088Abstract: An amide compound of the formula (I): ? wherein R is amino and the like, A is alkylene and the like, X is O, S and the like, M is arylene and the like, R1, R2, R3 and R4 are H, hydroxy and the like, R5 is H, alkyl and the like, m is an integer of 0-6, R6 is an optionally substituted aryl and the like, and R7 is H, an optionally substituted alkyl and the like, a pharmaceutically acceptable acid addition salt thereof and a pharmaceutical containing same as an active ingredient. The amide compounds exhibit superior suppressive effects on cytokines directly or indirectly involved in inflammations, such as IL-8, IL-1, IL-6, TNF-?, GM-CSF and the like, and are useful for the prophylaxis and treatment of rheumatic diseases, arthritis due to gout and the like.Type: GrantFiled: August 15, 1996Date of Patent: May 2, 2006Assignee: Japan Tobacco, Inc.Inventors: Junichi Haruta, Kazuhiko Sakuma, Yoshihiro Watanabe